Clinical Trials Logo

BRCA2 Mutation clinical trials

View clinical trials related to BRCA2 Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05748353 Active, not recruiting - Breast Cancer Clinical Trials

Endocrine Disruptors and Life STILe in Breast Cancer Development

STILVARCA
Start date: January 1, 2012
Phase:
Study type: Observational

The aim of the study is to evaluate the role of lifestyle and environmental factors ( environmental contaminants such as Cd) on the penetrance of BRCA1/2 genes in BRCAm patients with Breast cancer and/or Ovarian cancer and in BRCAm healthy women without cancer diagnosis

NCT ID: NCT05448963 Active, not recruiting - Breast Cancer Clinical Trials

Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy

Start date: July 30, 2022
Phase: N/A
Study type: Interventional

Nipple-sparing mastectomy (NSM) is indicated for breast cancer requiring total mastectomy and without nipple involvement by cancer. Robot-assisted mastectomy enables removal of the whole breast tissue with well-preserved breast skin envelope through a single longitudinal incision in the anterior axillary line at the nipple areolar level. The next-generation robot, da Vinci SP system, is single-armed, equipped with multiple flexible instruments and camera, which is likely to improve the efficacy of robotic mastectomy. The investigator's scope of this study is to establish the feasibility and safety of SP-applied NSM through this single-armed pilot trial. Participants with breast cancer indicated for nipple-sparing mastectomy or candidates of prophylactic mastectomy carrying germline pathogenic or likely pathogenic BRCA1/2 mutations are recruited to receive SP-assisted unilateral or bilateral NSMs. Immediate breast reconstruction is followed according to the mode of the plastic surgeon's clinical decision. The primary endpoint is technical feasibility, and the secondary endpoint is safety and patient-reported outcome.

NCT ID: NCT03685331 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Start date: October 15, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

NCT ID: NCT03351803 Active, not recruiting - BRCA1 Mutation Clinical Trials

BRCA Founder OutReach (BFOR) Study

BFOR
Start date: November 10, 2017
Phase:
Study type: Observational

The purpose of this study is to learn how to provide BRCA gene testing to a larger number of people as well as to make testing part of a person's regular medical care.

NCT ID: NCT01608074 Active, not recruiting - BRCA1 Mutation Clinical Trials

Radical Fimbriectomy for Young BRCA Mutation Carriers

Fimbriectomy
Start date: December 2011
Phase: N/A
Study type: Interventional

Some BRCA-mutated women are reluctant to undergo laparoscopic bilateral salpingo-oophorectomy. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion.